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ABSTRACT
Background: Guidelines recommend an early invasive
strategy for patients with diabetes with acute coronary
syndromes (ACS). We investigated if patients with
diabetes with ACS are offered coronary angiography
(CAG) and revascularisation to the same extent as
patients without diabetes.
Methods and results: The study is a nationwide
cohort study linking Danish national registries
containing information on healthcare. The study
population comprises all patients hospitalised with
first-time ACS in Denmark during 2005–2007
(N=24 952). Diabetes was defined as claiming of a
prescription for insulin and/or oral hypoglycaemic
agents within 6 months prior to the ACS event.
Diabetes was present in 2813 (11%) patients.
Compared with patients without diabetes, patients with
diabetes were older (mean 69 vs 67 years, p<0.0001),
less often males (60% vs 64%, p=0.0001) and had
more comorbidity. Fewer patients with diabetes
underwent CAG: cumulative incidence 64% vs 74% for
patients without diabetes, HR=0.72 (95% CI 0.69 to
0.76, p<0.0001); adjusted for age, sex, previous
revascularisation and comorbidity HR=0.78 (95% CI
0.74 to 0.82, p<0.0001). More patients with diabetes
had CAG showing two-vessel or three-vessel disease
(53% vs 38%, p<0.0001). However, revascularisation
after CAG revealing multivessel disease was less likely
in patients with diabetes (multivariable adjusted
HR=0.76, 95% CI 0.68 to 0.85, p<0.0001).
Conclusions: In this nationwide cohort of patients
with incident ACS, patients with diabetes were found to
be less aggressively managed by an invasive treatment
strategy. The factors underlying the decision to defer
an invasive strategy in patients with diabetes are
unclear and merit further investigation.
INTRODUCTION
An increasing proportion of patients hospita-
lised with acute coronary syndromes (ACS)
have concomitant diabetes. This patient
group has an adverse prognosis, including a
higher long-term mortality rate, which is not
fully explained by a clustering of risk factors
and more comorbidity in patients with dia-
betes.1–4 Several studies have proven the
beneﬁt of an invasive strategy in patients with
diabetes of at least the same magnitude as
in patients without diabetes in the setting
of ST-elevation myocardial infarction
(STEMI)5–7 as well as non-ST-elevation
KEY MESSAGES
What is already known about this subject?
▸ Patients presenting with acute coronary syn-
dromes (ACS) and concomitant diabetes mellitus
(DM) constitute a high-risk group and have a
more adverse prognosis than patients without
DM. Despite randomised clinical trials showing
a benefit of an early invasive strategy in patients
with diabetes presenting with ACS of at least the
same magnitude as in patients without DM,
prior reports suggest an underuse of evidence-
based medication and cardiac catheterisation in
this subset of patients.
What does this study add?
▸ In this nationwide study of patients with incident
ACS in a modern invasive treatment setting, we
found that patients with DM remained a high-
risk group, but were significantly less likely to
undergo coronary angiography and subsequent
revascularisation than patients without DM, even
after adjusting for conventional risk factors.
Noticeably, in the subgroup of patients with an
available angiogram showing multivessel
disease, patients with DM were not as aggres-
sively revascularised as patients without DM.
How might this impact on clinical practice?
▸ Our findings suggest that physicians need to be
aware of a potential treatment-risk paradox with an
underuse of invasive treatment strategies in
patients with DM hospitalised with ACS. However,
future studies are needed to further clarify the
reasons why physicians refrain from using cardiac
catheterisations in patients with DM.
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ACS.8 9 Thus, current and previous guidelines recom-
mend an early invasive strategy for patients with diabetes
with ACS.10–13 In Denmark, guidelines have recom-
mended an immediate invasive strategy for all patients
with STEMI following the results of the DANAMI 2 trial,6
and an early invasive strategy for patients without STEMI
following the publication of the FRISC 2 trial.14
Importantly, observational studies have found that adher-
ence to guidelines improves outcome.15 16
Nonetheless, several previous reports have elucidated
underuse of evidence-based medication and cardiac
catheterisation in patients with ACS with diabetes.3 17–19
Some of these reports contain data that are not contem-
porary and therefore with a low overall rate of invasive
examination.3 17 18 In one study, the lower frequency of
cardiac catheterisation was conﬁned to insulin-
dependent patients with diabetes and based on
in-hospital data only.19 Other studies have found no dis-
parities in cardiac catheterisation rates in patients with
and without diabetes.20–22
The present study was performed in order to evaluate
if patients with diabetes with ACS are offered coronary
angiography (CAG) and revascularisation to the same
extent as patients without diabetes in a contemporary
real-world setting. For this purpose we used nationwide
registries to investigate all admissions for ACS in
Denmark (5.4 million inhabitants) in 2005–2007.
METHODS
Study population
The study was designed as a retrospective observational
nationwide cohort study linking Danish national regis-
ters containing information on vital status, hospitalisa-
tions, revascularisation procedures, coronary pathology
revealed by CAG and claiming of drug prescriptions.
The method and study population have been described
in detail previously.23
Information on admissions and comorbidity was
obtained from the Danish National Patient Registry,
which holds information on all admissions to all Danish
hospitals since 1978. Each hospitalisation is registered by
one primary ﬁnal discharge diagnosis and, if appropri-
ate, one or more secondary diagnoses according to the
International Classiﬁcation of Diseases (ICD)—the 8th
revision (ICD-8) before 1994 and the 10th revision
(ICD-10) after 1994.
All patients, 30–90 years of age, admitted with acute
myocardial infarction (MI), including STEMI and
non-STEMI (NSTEMI), or unstable angina pectoris
(UAP) as the primary discharge diagnosis (ICD-10
codes: I20.0, I21) in the period January 2005 through
December 2007, were identiﬁed. To study ﬁrst admis-
sions with ACS, we excluded patients with a previous
diagnosis of MI 1978–1993 (using ICD-8 code 410), or
ACS since 1994. The deﬁnitions of MI and UAP in
Denmark follow the guidelines from the European
Society of Cardiology. Patients discharged on the day of
admission were excluded to ensure that the ACS diagno-
sis was based on reliable observations including sampling
of biochemical markers. Likewise, patients not surviving
the day of admission were excluded in order to avoid
the potential bias that these patients would not be eli-
gible for cardiac catheterisation due to early death
shortly after their admission. The MI diagnosis in the
registry has been validated by comparison with the
results from the MONICA database, revealing a high
sensitivity and speciﬁcity of 90–95%.24
Exposure variable
Diabetes was deﬁned as claiming of a prescription for
insulin and/or oral hypoglycaemic agents (OHA) within
6 months prior to the ACS event. Thus, patients diag-
nosed with diabetes mellitus during the index admission
for ACS were not included in the diabetes group.
Information on drug prescription was obtained from
The Danish Register of Medicinal Product Statistics,
which includes information about all prescriptions dis-
pensed from pharmacies in Denmark since 1995. As all
residents in Denmark are covered by a national health
insurance system and get the cost of drugs partly reim-
bursed, all pharmacies are required by law to register on
an individual level all prescriptions dispensed.
Explanatory variables
Information on the extent of coronary artery disease
among patients examined by CAG was obtained from
the Danish Heart Registry (http://si-folkesundhed.dk/
Links/Dansk%20Hjerteregister.aspx), which includes all
invasive examinations and procedures performed at
Danish hospitals since year 2000. A signiﬁcant lesion was
deﬁned as at least 50% diameter stenosis in a major epi-
cardial vessel or coronary artery bypass graft (CABG).
Primary and secondary diagnoses at the index admis-
sion and at admissions up to 1 year before the index
admission were used to deﬁne comorbidity. Diagnoses of
congestive heart failure, cardiogenic shock, arrhythmia
and pulmonary oedema were considered, reﬂecting the
severity of the heart disease, while diagnoses of malig-
nancy, cerebrovascular disease, acute renal failure and
chronic renal failure indicated comorbidity. This
method is an extension of the Ontario MI mortality pre-
diction rule25 with translation to ICD-10 codes validated
by So et al.26 The age of each patient was categorised
into 10 year intervals and was used as a categorical
variable.
Previous revascularisation within 5 years of index event
was recorded for each patient, as this might affect the
decision to perform an invasive examination.
Outcome
Information on the patient’s vital status was obtained
from The Danish Civil Registration System. We estimated
the effect of diabetes on the chance of CAG and on sub-
sequent revascularisation (percutaneous coronary inter-
vention (PCI) or CABG) for those having had a CAG
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performed within 60 days of admission. A 60-day obser-
vation period was used to include as many examinations
and procedures as possible and, at the same time, to
avoid angiography performed because of reinfarctions.
Since differences in mortality could potentially inﬂuence
the rates of procedures, we used a competing risks
model to analyse the data.27 Cumulative incidence
curves were calculated for the incidence of CAG in the
whole study population and of revascularisation in the
CAG population, and the cumulative incidence at
60 days was read from the curves.
Differences in clinical presentation of disease could
affect the timing of the invasive CAG. We therefore per-
formed a stratiﬁed analysis of CAG procedures, dividing
them into acute or early invasive examination, being on
the day of admission or the day after, and subacute from
day 2 until day 60.
Statistical methods
Discrete data are presented as frequencies and percen-
tages. Continuous variables are presented as mean with
SD for characteristics with appropriately near-symmetrical
distributions or as median (IQR). Differences in baseline
characteristics between patients with and without dia-
betes were evaluated using a χ2 test for categorical vari-
ables and the non-parametric Mann-Whitney U test for
continuous variables.
Cumulative incidence curves were estimated in a com-
peting risks model with the SAS-macro developed by
Rosthoj et al.28 Differences in outcome were estimated
using Cox proportional hazards model. Outcome vari-
ables were CAG in the entire population and revasculari-
sation (PCI or CABG) in patients in whom CAG was
performed. In the multivariable analysis, covariates con-
sidered to have potential impact on the decision to
perform CAG and subsequent revascularisation were
entered in three steps. First, the basic confounder’s age
and sex were entered. Second, year of admission prior
PCI or CABG, and comorbidity were added to the
model. Lastly, socioeconomic variables were added.
Model assumptions—linearity, proportional hazards and
interactions—were tested and found valid unless other-
wise indicated. All hypotheses tested had a 0.05 signiﬁ-
cance level. All tests were two-sided. Since an interaction
between diabetic status and number of diseased vessels
found by CAG with regard to chance of revascularisation
was found, separate Cox analyses were performed for
one-vessel, two-vessel and three-vessel disease.
As a sensitivity analysis, we used propensity score ana-
lysis to identify a set of cases (patients with diabetes)
and controls (patients without diabetes), who were
matched with respect to age, comorbidity, admission
year, admission diagnosis and previous revascularisation.
A propensity score was quantiﬁed by multivariable logis-
tic regression. Concordance statistic (C statistic) of the
model was 0.77, indicating good discriminative capabil-
ities between the two exposure groups.29 A Greedy
matching macro (by Lori S Parsons, accessed 14 April
2009, at http://www2.sas.com/proceedings/sugi26/
p214-26.pdf) was used to match each case to one
control. A multivariable-adjusted Cox-model was ﬁtted,
including the propensity score. All analyses were per-
formed with SAS statistical software package V.9.13 (SAS
Institute, Inc, Cary, North Carolina, USA).
RESULTS
Demographic data
During the 3-year study period 24 952 patients were hos-
pitalised with ﬁrst-time ACS and survived the ﬁrst day.
Diabetes was present in 2813 (11%) patients. Among
these, 60% were treated with OHA, 12% with insulin,
and 28% with a combination of insulin and OHA.
Baseline characteristics for patients with and without dia-
betes are presented in table 1. Compared with patients
without diabetes, patients with diabetes were older
(mean 69 vs 67 years, p<0.0001), less often male (60% vs
64%, p=0.0001) and had more comorbidity, in particu-
lar, cardiovascular and renal diseases, but not malignant
diseases. In accordance with the higher frequency of
comorbidities, patients with diabetes were prescribed
more medications prior to the ACS hospitalisation.
Patients with diabetes had lower socioeconomic status,
but lived as close to the invasive centres as patients
without diabetes. Few patients had been revascularised
within the preceding 5 years (5.3% in the diabetic group
and 3.3% in the non-diabetic group, p<0.001). The ﬁnal
diagnosis was acute MI in 83% and unstable angina in
17%, with no difference between patients with and
without diabetes. Information about race was not avail-
able, but the vast majority of patients in Denmark are
Caucasian. During the 60-day follow-up, 380 (13%)
patients with diabetes and 2008 (9%) patients without
diabetes died (ﬁgure 1, table 2).
Coronary angiography
Fewer patients with diabetes underwent CAG: cumulative
incidence 64% vs 74% for patients without diabetes
(ﬁgure 2), HR=0.72, 95% CI 0.69 to 0.76, p<0.0001.
Adjustment for age, sex, previous revascularisation,
comorbidity and socioeconomic variables did not change
the estimate substantially: HR=0.79 (95% CI 0.76 to 0.83,
p<0.0001; table 3). In the propensity score matched ana-
lysis, 2626 patients with diabetes were matched
one-to-one with 2626 patients without diabetes. The pro-
pensity adjusted Cox model yielded a HR of 0.88 (95% CI
0.82 to 0.94, p=0.0001). The lower CAG rate was espe-
cially pronounced for acute invasive investigation per-
formed on the day of admission or the day after (25% vs
37%, p<0.0001; table 2). Multivariable adjustment for the
possible confounders mentioned above conﬁrmed this
result: HR for CAG on the day of admission or the day
after ACS was 0.69 (0.64 to –0.75, p<0.0001), while HR
for CAG on day 2–60 after ACS was 0.88 (0.82 to 0.94,
p<0.0001) comparing patients with and without diabetes.
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In ﬁgure 3, the results of CAG in the diabetic and
non-diabetic groups are depicted. More patients with
diabetes had CAG showing two-vessel or three-vessel
disease (53% vs 38%, p<0.0001).
Revascularisation
Overall, the frequency of revascularisation (PCI or CABG)
in patients with diabetes was substantially lower than in
patients without diabetes (47% vs 57%, p<0.0001; table 2).
This was partly explained by a lower CAG rate in patients
with diabetes. Considering only patients who were inva-
sively investigated by CAG, 73% of patients with diabetes
and 77% of patients without diabetes were revascularised
(p=0.0002). The frequency and method (PCI and/or
CABG) of revascularisation differed according to diabetic
status and number of diseased vessels (table 4). The differ-
ence in revascularisation rates between patients with and
without diabetes increased with more severe coronary path-
ology. In one-vessel and two-vessel disease, the frequencies
of PCI were lower in patients with diabetes. In three-vessel
disease both rates of PCI and of CABG were lower.
Multivariable analyses revealed no signiﬁcant difference
between patients with and without diabetes in chance of
revascularisation if CAG had shown one-vessel disease
(table 5). However, patients with diabetes with multivessel
disease had a 24% less chance of being revascularised.
Table 1 Baseline characteristics of patients with and without diabetes
Diabetes
N=2813 (11)
No diabetes
N=22 139 (89) p Value
Male gender 1692 (60) 14 128 (64) 0.0001
Age in years, mean (SD) 69.2 (11.8) 67.0 (13.1) <0.0001
Hospital stay in days, median (Q1-Q3) 7 (4–12) 6 (4–10) <0.0001
Distance to invasive centre 0.19
Close (<21 km) 946 (34) 7275 (33)
Intermediate distance (21–64 km) 880 (31) 7340 (33)
Long distance (>64 km) 984 (35) 7485 (34)
Unknown 3 (0.1) 39 (0.2)
Revascularisation within the past 5 years 150 (5) 733 (3) <0.0001
Comorbidity
Congestive heart failure 447 (16) 2061 (9) <0.0001
Pulmonary oedema 42 (2) 157 (1) <0.0001
Shock 23 (1) 123 (1) 0.09
Arrhythmia 417 (15) 2492 (11) <0.0001
Cerebrovascular disease 235 (8) 994 (5) <0.0001
Chronic obstructive pulmonary disease 196 (7) 1288 (6) 0.02
Chronic renal failure 109 (4) 297 (1) <0.0001
Acute renal failure 50 (2) 176 (1) <0.0001
Malignancy 71 (3) 583 (3) 0.73
Educational level <0.0001
Elementary school 1284 (46) 8239 (37)
High school 947 (34) 8750 (40)
Bachelor or higher 276 (10) 2973 (13)
Unknown 306 (11) 2177 (10)
Income <0.0001
Low 1099 (39) 7001 (32)
Medium 953 (34) 7211 (33)
High 746 (27) 7823 (35)
Unknown 15 (1) 104 (1)
Living alone 1236 (44) 8103 (37) <0.0001
Discharge diagnosis 0.14
Acute myocardial infarction 2322 (83) 18 515 (84)
Unstable angina pectoris 491 (17) 3624 (16)
Medication before admission
Loop diuretics 910 (32) 2671 (12) <0.0001
Lipid lowering drugs 1454 (52) 4129 (19) <0.0001
β blockers 854 (30) 4661 (21) <0.0001
ACE-I/ARB 1680 (60) 5273 (24) <0.0001
Aspirin 1390 (49) 5964 (27) <0.0001
Clopidogrel 121 (4) 487 (2) <0.0001
Values are numbers with percentage in parenthesis unless otherwise indicated.
ACE-I/ARB, ACE inhibitors/angiotensin receptor blockers.
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DISCUSSION
The main results of this study are that patients with ACS
with diabetes in the modern invasive treatment era
remain a high-risk group but, paradoxically, CAG is per-
formed signiﬁcantly less often in these patients.
Furthermore, among the patients with ACS who under-
went CAG, the angiogram in patients with diabetes more
often revealed multivessel disease, which was not revas-
cularised as often as for patients without diabetes.
The prevalence of diabetes in the current cohort is
somewhat lower than in most other studies, which is
most likely explained by the fact that only patients with
ﬁrst-time ACS were included and that diet-treated
patients with diabetes were not categorised as having dia-
betes.1 3 4 17–22 Also, the prevalence of diabetes in
Denmark is lower than in many other industrialised
countries including, especially, North America. Total
mortality at 60 days was 9.6% with an almost 50% higher
mortality rate in patients with diabetes. The total mortal-
ity in the current study is rather high, which can be
explained by the nature of the study population com-
prising unselected patients with an age up to 90 years.
The excess mortality in patients with diabetes has a mag-
nitude similar to that found in previous studies.1–4
Some conditions, such as cancer with short expected
lifetime, very old age and severe renal disease, should in
fact prevent an invasive investigation. Despite inclusion of
these factors in the multivariable statistical analyses, the
chance of CAG was found to be about 20% less for
patients with diabetes. Since patients with diabetes had
lower socioeconomic status, and a previous study has indi-
cated that patients’ income affects the chance of revascu-
larisation—even in Denmark, where all patients are
covered by a universal health insurance30—socio-
economic variables were also accounted for in the statis-
tical models without affecting the estimate. A putative
explanation that could not be accounted for in the
current study is that patients with diabetes to a higher
degree did not accept an invasive strategy even though
this examination was recommended by the physician.
However, few patients decline recommended interven-
tions, and it seems unlikely that this could explain the
large difference in CAG rate.31 Furthermore, post-MI
complications such as heart failure and renal dysfunction,
which are more common in patients with diabetes and
might prevent an invasive strategy, could not be
accounted for. Conversely, a time period of 60 days after
the ACS event was applied, that is, CAG procedures per-
formed after discharge in stabilised patients were
included in the analyses. A variety of barriers can prevent
physicians from adhering to guidelines. Apart from exter-
nal factors, the barriers might comprise lack of awareness,
lack of agreement with guidelines and inertia of previous
practice.32 The last mentioned factors should not be rele-
vant to this matter, since large well conducted studies on
the effect of an invasive strategy were published several
years before the data collection for the current study.
Lack of awareness regarding the use of risk scores in
non-ST-segment elevation ACS, such as the GRACE risk
score, which has been proven to be beneﬁcial, might
however be a relevant factor.33 Guidelines on risk stratiﬁ-
cation in ACS before 2005, when this study started,
focused on ECG changes and biomarker level but not on
the use of risk scores, although diabetes was mentioned
as a risk factor.11 Also, insights from the CRUSADE
Table 2 Incidence of death, CAG and revascularization,
in patients with and without diabetes
Diabetes
N=2813
(11)
No
diabetes
N=22 139
(89) p Value
Death within 60 days 380 (13) 2008 (9) <0.0001
Acute* CAG 698 (25) 8170 (37) <0.0001
Acute* revascularisation 584 (21) 7123 (32) <0.0001
CAG within 60 days 1796 (64) 16 466 (74) <0.0001
Revascularisation within
60 days
1310 (47) 12 655 (57) <0.0001
Data are presented as numbers, percentages in parenthesis.
*Acute is defined as the day of admission or the next day.
CAG, coronary angiography.
Figure 1 Mortality during the
first 60 days after first-time acute
coronary syndrome in patients
with and without diabetes.
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Quality Improvement Initiative in the USA34 and the
Canadian ACS registries have revealed that physician risk
stratiﬁcation is suboptimal, resulting in a treatment-risk
paradox implicating a lower chance of undergoing CAG
in high-risk patients who more often have diabetes.35–37
Improving adherence to guidelines and quality of patient
care encompass comprehensive approaches at different
levels. The most effective approaches seem to be inter-
active educational meetings, the use of feedback systems,
computerised decision support and combined interven-
tions.38 Whether application of these methods will result
in greater utilisation of an invasive strategy in patients
with high-risk diabetic ACS remains to be determined.
The acute CAG rate was particularly low for patients
with diabetes, which might partly be explained by differ-
ences in presentation between patients with and without
diabetes. Some studies have shown that patients with
ACS with diabetes present less often with STEMI,4 18
while others have not.2 20 Also, some studies have found
patients with diabetes to present less often with chest
pain2 20 and to have a greater delay from symptom onset
to hospital arrival.4 22 Unfortunately, the STEMI diagno-
sis in the Danish National Patient Registry has not been
validated and cannot be used for the current study.
However, if in the current study the proportion of
STEMI among patients with diabetes had been lower,
then the fraction of NSTEMI and UAP should have
been higher resulting in a higher rate of non-acute
CAG, which was not the case. Nevertheless, patients with
ACS with diabetes may beneﬁt more from early invasive
treatment than patients without diabetes emphasising
the importance of a quick diagnosis and referral for
CAG.39
The ﬁnding of more severe coronary artery disease in
patients with diabetes is in accordance with other
studies.4 20 33 To the best of our knowledge, no previous
studies have published data regarding PCI and CABG
rates according to ﬁndings of CAG in unselected
patients with ACS with diabetes. Data from the Euro
Heart survey have shown that angiography followed by
intervention is less common in patients with diabetes in
NSTEMI, but not in STEMI.4 In this report, no multi-
variable analyses were presented and data regarding pro-
cedures after discharge were incomplete. Our data
imply that most patients with ACS due to one-vessel
disease are revascularised without difference according
to diabetic status. However, for three-vessel disease the
revascularisation rate is lower, especially for patients with
diabetes, although the prognostic impact of revasculari-
sation has been well documented for this group.10 The
decision to defer revascularisation ought not to be based
on comorbidity in most cases, since a CAG should not
be performed if subsequent revascularisation is not an
option. Yet, there might be situations where patients are
offered CAG with the intention to perform PCI if pos-
sible but not CABG. After controlling for comorbidity
and other possible confounders, the statistical model
showed a striking 24% less chance of revascularisation in
Figure 2 Cumulative incidence
curves illustrating the chance of
coronary angiography in patients
with and without diabetes when
alive during the first 60 days after
first-time acute coronary
syndrome.
Table 3 Chance of coronary angiography within 60 days for patients with diabetes compared with patients without diabetes
admitted with acute coronary syndromes (N=24 952)
Model 1 Model 2 Model 3 Model 4
HR 0.72 0.74 0.78 0.79
95% CI 0.69 to 0.76 0.70 to 0.78 0.74 to 0.82 0.76 to 0.83
p Value <0.0001 <0.0001 <0.0001 <0.0001
Model 1: Unadjusted.
Model 2: Adjusted for age group and sex.
Model 3: Adjusted for age group, sex, year of admission, previous revascularisation and comorbidity.
Model 4: Adjusted for age group, sex, year of admission, previous revascularisation, comorbidity and socioeconomic variables (educational
level, income, living alone).
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patients with diabetes with both two-vessel and three-
vessel disease. The most likely explanation is that revas-
cularisation was not technically feasible due to a higher
frequency of diffuse and peripheral coronary artery
disease.40 Future studies investigating if this is the case
are needed. Also, research into alternative treatment
strategies for patients with diabetes with multivessel
disease without options for revascularisation is urgently
needed.
The strength of the present study is that the study
cohort is nationwide and therefore unselected. Owing to
the high quality of the national registries, many different
characteristics of the patients including result of CAG
are available.
The main limitation is that of the observational
register-based design. Only comorbidities registered
during hospitalisations were available, while milder
forms, for example, peripheral artery disease and renal
dysfunction managed out-of-hospital were not accounted
for. Likewise, information on ECG changes, biomarkers
and complications such as heart failure or renal failure
after the ACS event, which could also inﬂuence the deci-
sion to apply an invasive strategy, was not available. Thus,
unmeasured confounding cannot be ruled out.
Patients with diet-controlled diabetes, who were classi-
ﬁed as patients without diabetes in the current study, are
expected to have a better prognosis than patients with
diabetes requiring antidiabetic medication.2 Therefore,
patients with diet-controlled diabetes might have less
advanced coronary artery disease and comorbidity pre-
venting an invasive strategy. If, however, patients with
diet-treated diabetes are similar to patients with diabetes
requiring antidiabetic medication, then the presented
results are likely to underestimate the real difference in
CAG rate between patients with and without diabetes.
CONCLUSION
In this nationwide cohort of patients with ﬁrst-time ACS,
patients with diabetes were found to be less aggressively
managed by an invasive strategy. The factors underlying
Figure 3 Result of coronary angiogram among patients with
and without diabetes admitted with first-time acute coronary
syndrome (a significant stenosis was defined as at least 50%
diameter reduction in a major epicardial vessel or coronary
artery bypass graft).
Table 4 Frequency of revascularisation (PCI and/or CABG) within 60 days after acute coronary syndromes for patients with
and without diabetes according to number of diseased vessels revealed by coronary angiography
One-vessel disease
N (DM)=512
N (non-DM)=6956
Two-vessel disease
N (DM)=407
N (non-DM)=3515
Three-vessel disease
N (DM)=541
N (non-DM)=2872
PCI
DM 451 (88) 313 (77) 255 (47)
Non-DM 6302 (91) 3030 (86) 1539 (54)
p Value 0.06 <0.0001 0.006
CABG
DM 6 (1) 47 (12) 173 (32)
Non-DM 94 (1) 321 (9) 1037 (36)
p Value 0.73 0.11 0.07
PCI and/or CABG
DM 454 (89) 352 (87) 404 (75)
Non-DM 6360 (91) 3271 (93) 2392 (83)
p Value 0.03 <0.0001 <0.0001
Data are presented as numbers with percentages in parenthesis.
CABG, coronary artery bypass grafting; DM, diabetes mellitus; PCI, percutaneous coronary intervention.
Table 5 Chance of revascularisation within 60 days for
patients with diabetes compared with patients without
diabetes admitted with acute coronary syndromes
according to result of CAG
Result of CAG HR CI p Value
One-vessel disease
(N=7468)
0.92 0.83 to 1.01 0.07
Two-vessel disease
(N=3922)
0.76 0.68 to 0.85 <0.0001
Three-vessel disease
(N=3413)
0.76 0.68 to 0.85 <0.0001
Multivariable model with age group, sex, year of admission,
previous revascularization and comorbidity as covariates.
CAG, coronary angiography.
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the decision to defer an invasive strategy in patients with
diabetes are unclear and merit further investigation.
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